Do e-cigarettes help people to quit smoking?

Professor Chris Bullen, The University of Auckland, New Zealand
March 2022
Disclosure of interests

I have never received funding from the tobacco or e-cigarette industries, nor do I have any personal financial interests in these industries.

I am employed fulltime by the University of Auckland, New Zealand.

I hold grants and contracts for research and evaluation from the NZ Ministry of Health, Health Research Council of NZ, University of Auckland, Auckland Council and NZ Ministry of Foreign Affairs and Trade.
Outline

• Background to E-cigarettes
• Evidence from research on E-cigarettes and smoking cessation
• Evidence from research on safety
• Other concerns
• NZ experience
• Reflections and conclusions
What are e-cigarettes?

“Devices whose function is to vaporize and deliver to the lungs of the user a chemical mixture typically composed of nicotine, propylene glycol and other chemicals.”

- World Health Organization
Hon Lik
Types of vaping products
Questions about e-cigarettes

Individual health of smokers

- Do they help people quit smoking?
- Are they safe?

Public health

- Is there evidence of increase in quitting or a fall in smoking prevalence?
- Is there a gateway-to-smoking effect?
- What about ‘second hand’ exposure?
- Is there a health benefit?
- Is there an effect on smoking inequalities?
Diverse Perspectives

“Disruptive technology” that will end smoking
“Huge gains for public health if all smokers adopt e-cigarette use”

OR

“A distraction from the tobacco end game”
“A major threat to tobacco control – they will discourage quitting, renormalise smoking, recruit new cigarette smokers and strengthen the arm of Big Tobacco”
Do they help people quit smoking?

- On-line user survey (N=3587) in 2010
- 96% of respondents said e-cigarettes helped them quit
- 92% said they helped them reduce the number of cigarettes they smoked

Source: Etter and Bullen, 2011
E-cigarettes reduced urge to smoke and delivered nicotine

Change in desire to smoke from baseline over the first hour after each product use:
E-cigarette vs nicotine inhalator vs cigarette

<table>
<thead>
<tr>
<th>Product</th>
<th>Mean tmax (min) (95% CI)</th>
<th>Mean Cmax (mg/mL) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usual cigarette (N=9)</td>
<td>14.3 (8.8 - 19.9)</td>
<td>13.4 (6.5 - 20.3)</td>
</tr>
<tr>
<td>16 mg E cig (N=8)</td>
<td>19.6 (4.9 - 34.20)</td>
<td>1.3 (0.0-2.6)</td>
</tr>
<tr>
<td>Nicorette inhalator (N=10)</td>
<td>32.0 (18.7 - 45.3)</td>
<td>2.1 (1.0-3.1)</td>
</tr>
</tbody>
</table>

Source: Bullen et al, Tob Control 2010
Unprecedented uptake by smokers

- A cigarette substitute
- Health concerns with smoking
- More acceptable and satisfying than NRT inhaler
- Convenience
- Affordability
- Social support
- ‘Viral’ movement
- Online information
- New identity
- Hobby
- Regulatory vacuum

Source: Barbeau et al, 2013; Steinberg et al, 2014
In general, the faster the nicotine delivery the product is likely to:
• be more satisfying
• be better at alleviating tobacco withdrawal symptoms
• have greater dependence liability

The ASCEND trial

Electronic cigarettes for smoking cessation: a randomised controlled trial

Christopher Bullen, Colin Hove, Murray Langat, Hayden McRobbie, Varsha Pareg, Jonathan Willmott, Natalie Walker

Summary

Background Electronic cigarettes (e-cigarettes) can deliver nicotine and mitigate tobacco withdrawal and are used by many smokers to assist quit attempts. We investigated whether e-cigarettes are more effective than nicotine patches at helping smokers to quit.

Methods We did this pragmatic randomised-controlled superiority trial in Auckland, New Zealand, between Sept 6, 2011, and July 5, 2013. Adult (≥18 years) smokers wanting to quit were randomised (with computerised block randomisation, block size nine, stratified by ethnicity [Maori Pacific; or non-Maori, non-Pacific], sex [men or women], and level of nicotine dependence [≥5 or ≤5 Fagerström test for nicotine dependence]) in a 4:4:1 ratio to 16 mg nicotine e-cigarettes, nicotine patches (21 mg patch, one daily), or placebo e-cigarettes (no nicotine), from 1 week before until 12 weeks after quit day, with low intensity behavioural support via voluntary telephone counselling. The primary outcome was biochemically verified continuous abstinence at 6 months (exhaled breath carbon monoxide measurement <10 ppm). Primary analysis was by intention to treat. This trial is registered with the Australasian New Zealand Clinical Trials Registry, number ACTRN12609000866900.

Findings 657 people were randomised (289 to nicotine e-cigarettes, 295 to patches, and 73 to placebo e-cigarettes) and were included in the intention-to-treat analysis. At 6 months, verified abstinence was 7.3% (21 of 289) with nicotine e-cigarettes, 5.8% (17 of 295) with patches, and 4.1% (three of 73) with placebo e-cigarettes (risk difference for nicotine e-cigarettes vs patches 1.5% [95% CI –2.4 to 5.3]; vs nicotine patches 3.6% [95% CI –1.2 to 8.4]). Achievement of abstinence was substantially lower than we anticipated for the power calculation, thus we had insufficient statistical power to conclude superiority of nicotine e-cigarettes to patches or to placebo e-cigarettes. We identified no significant differences in adverse events, with 137 events in the nicotine e-cigarettes group, 119 events in the patches group, and 36 events in the placebo e-cigarettes group. We noted no evidence of an association between adverse events and study product.

Interpretation E-cigarettes, with or without nicotine, were modestly effective at helping smokers to quit, with similar achievement of abstinence as with nicotine patches, and few adverse events. Uncertainty exists about the place of e-cigarettes in tobacco control, and more research is urgently needed to clearly establish their overall benefits and harms at both individual and population levels.

Funding Health Research Council of New Zealand.

Bullen et al, Lancet 2013
### E-cigarettes as effective as patches

<table>
<thead>
<tr>
<th>Study</th>
<th>Nicotine EC</th>
<th>Nicotine Patch</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullen 2013</td>
<td>7% (21/289)</td>
<td>6% (17/295)</td>
<td>1.26 (0.68 – 2.34)</td>
</tr>
</tbody>
</table>

#### Risk Ratio

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Control Events</th>
<th>Total Weight</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullen 2013</td>
<td>21</td>
<td>17</td>
<td>100.0%</td>
<td>1.26 [0.68, 2.34]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>289</td>
<td>295</td>
<td>100.0%</td>
<td>1.26 [0.68, 2.34]</td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: $Z = 0.73$ (P = 0.46)
Nicotine vs Non-Nicotine e-cigarettes

<table>
<thead>
<tr>
<th>Study</th>
<th>Nicotine EC</th>
<th>Placebo EC</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullen 2013</td>
<td>7% (21/289)</td>
<td>4% (3/73)</td>
<td>1.77 (0.54 – 5.77)</td>
</tr>
<tr>
<td>Caponnetto 2013</td>
<td>11% (22/200)</td>
<td>4% (4/100)</td>
<td>2.75 (0.97 – 7.76)</td>
</tr>
<tr>
<td>Total</td>
<td>9% (43/489)</td>
<td>4% (7/173)</td>
<td>2.29 (1.05 – 4.96)</td>
</tr>
</tbody>
</table>

Caveats

• Although 2 e-cig RCTs were well conducted and judged to be at low risk of bias, the quality of the evidence overall was categorized by the Cochrane methodology as low because based on only 2 trials

• RCTs used now-obsolete products that delivered small amounts of nicotine
<table>
<thead>
<tr>
<th></th>
<th>EC (N=438)</th>
<th>NRT (N=446)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-year sustained quit rates</td>
<td>18.1%</td>
<td>9.9%</td>
<td>1.83 (1.30 to 2.58)</td>
</tr>
</tbody>
</table>

**TEC Study (2019)** – 1-year sustained quit rates

The New England Journal of Medicine

**A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy**

Peter Hajek, Ph.D., Anna Phillips-Waller, B.Sc., Dunja Przulj, Ph.D., Francesca Pesola, Ph.D., Katie Myers Smith, D.Psych., Natalie Bisal, M.Sc., Jinshuo Li, M.Phil., Steve Parrott, M.Sc., Peter Sasieni, Ph.D., Lynne Dawkins, Ph.D., Louise Ross, Maciej Goriewicz, Ph.D., Pharm.D., Qi Wu, M.Sc., and Hayden J. McRobbie, Ph.D.
ASCEND II Study (2019) – 6 month quit rates

Pragmatic, three-arm, community-based randomized trial undertaken in New Zealand (2015-2018).

Participants were randomized (1:4:4 ratio) to 14 weeks of
- 21mg nicotine patches
- 21mg nicotine patches and 18mg nicotine ECs, or
- 21mg nicotine patches and nicotine-free ECs.

Minimal behavioural support

<table>
<thead>
<tr>
<th>Nic EC + patch (n=500)</th>
<th>No nic EC+ patch (n=499)</th>
<th>Relative Risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7%</td>
<td>4%</td>
<td>1.75 (1.02 to 2.98)</td>
</tr>
</tbody>
</table>

Walker, Bullen et al. 2019
Electronic cigarettes for smoking cessation

 Jamie Hartmann-Boyce, Hayden McRobbie, Ailsa R Butler, Nicola Lindson, Chris Bullen, Rachna Begh, Annika Theodoulou, Caitlin Notley, Nancy A Rigotti, Tari Turner, Thomas R Fanshawe, Peter Hajek  

Authors' declarations of interest

Version published: 14 September 2021  

https://doi.org/10.1002/14651858.CD010216.pub6

61 completed studies, 16,759 participants, 34 RCTs. 5/61 included studies new to update.
Nicotine EC vs NRT for smoking cessation

### Analysis 1.1. Comparison 1: Nicotine EC versus NRT, Outcome 1: Smoking cessation

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>EC</th>
<th>NRT</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>Bullen 2013</td>
<td>21</td>
<td>289</td>
<td>17</td>
<td>295</td>
<td>1.26 [0.68, 2.34]</td>
</tr>
<tr>
<td>Hajek 2019</td>
<td>79</td>
<td>438</td>
<td>44</td>
<td>446</td>
<td>1.83 [1.30, 2.58]</td>
</tr>
<tr>
<td>Lee 2018</td>
<td>5</td>
<td>20</td>
<td>1</td>
<td>10</td>
<td>2.50 [0.34, 18.63]</td>
</tr>
<tr>
<td>Russell 2021 (1)</td>
<td>34</td>
<td>140</td>
<td>15</td>
<td>70</td>
<td>1.13 [0.66, 1.94]</td>
</tr>
<tr>
<td>Russell 2021 (2)</td>
<td>44</td>
<td>145</td>
<td>15</td>
<td>71</td>
<td>1.44 [0.86, 2.40]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>1032</td>
<td>892</td>
<td>100.0%</td>
<td>1.53 [1.21, 1.93]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>183</td>
<td>92</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>Chi² = 2.90, df = 4 (P = 0.58); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect:</td>
<td>Z = 3.60 (P = 0.0003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Analysis 3.1. Comparison 3: Nicotine EC versus non-nicotine EC, Outcome 1: Smoking cessation

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Nicotine EC</th>
<th>Non-nicotine EC</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullen 2013</td>
<td>21</td>
<td>3</td>
<td>1.77 [0.54, 5.77]</td>
</tr>
<tr>
<td>Caponnetto 2013a</td>
<td>22</td>
<td>4</td>
<td>2.75 [0.97, 7.76]</td>
</tr>
<tr>
<td>Cobb 2021 (1)</td>
<td>4</td>
<td>0</td>
<td>4.53 [0.25, 82.96]</td>
</tr>
<tr>
<td>Cobb 2021 (2)</td>
<td>10</td>
<td>1</td>
<td>5.00 [0.65, 38.22]</td>
</tr>
<tr>
<td>Eisenberg 2020</td>
<td>5</td>
<td>3</td>
<td>1.65 [0.40, 6.77]</td>
</tr>
<tr>
<td>Lucchioni 2020</td>
<td>13</td>
<td>11</td>
<td>1.18 [0.57, 2.46]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>947</td>
<td>500</td>
<td>1.94 [1.21, 3.13]</td>
</tr>
</tbody>
</table>

Total events: 75  22

Heterogeneity: Chi² = 3.44, df = 5 (P = 0.63); I² = 0%
Test for overall effect: Z = 2.74 (P = 0.006)
Test for subgroup differences: Not applicable

Footnotes
(1) 8 mg/ml arm; control group split to avoid double-counting
(2) 36 mg/ml arm; control group split to avoid double-counting
Analysis 4.1. Comparison 4: Nicotine EC versus behavioural support only/no support, Outcome 1: Smoking cessation

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Nicotine EC</th>
<th>Usual care</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Begh 2021</td>
<td>7</td>
<td>164</td>
<td>3</td>
<td>161</td>
</tr>
<tr>
<td>Dawkins 2020</td>
<td>3</td>
<td>48</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>Eisenberg 2020</td>
<td>5</td>
<td>128</td>
<td>1</td>
<td>121</td>
</tr>
<tr>
<td>Halpern 2018</td>
<td>4</td>
<td>1199</td>
<td>0</td>
<td>813</td>
</tr>
<tr>
<td>Holliday 2019 (1)</td>
<td>6</td>
<td>40</td>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>Lucchieri 2020</td>
<td>13</td>
<td>70</td>
<td>7</td>
<td>70</td>
</tr>
</tbody>
</table>

Total (95% CI):

<table>
<thead>
<tr>
<th>Nicotine EC</th>
<th>Usual care</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Total</td>
<td>M-H, Fixed, 95% CI</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>1649</td>
<td>1237</td>
<td>100.0%</td>
<td>2.61 [1.44, 4.74]</td>
</tr>
</tbody>
</table>

Total events: 38

Heterogeneity: Chi² = 1.46, df = 5 (P = 0.92); I² = 0%

Test for overall effect: Z = 3.16 (P = 0.002)

Test for subgroup differences: Not applicable

Footnotes:

(1) Although participants were given a choice of nicotine concentration including 0 mg, none of the participants chose the non-nicotine e-liquid
Daily use of e-cigarettes is important

Using data from wave 1 and wave 2 of the US Population Assessment of Tobacco and Health Study, daily e-cigarette users were more likely to have reduced their cigarette use and quit smoking cigarettes compared with non-users.

Source: Berry et al, 2017
Quit attempt rate and annual cessation rate from 2001-02 to 2014-15, USA

CPS-TUS
(Current Population Survey-Tobacco Use Supplement)

Source: Zhu et al. BMJ 2017
Public Health England maintains vaping is 95% less harmful than smoking

As scepticism rises, PHE says e-cigarettes could help more people quit smoking
Substances that are potentially harmful

Aerosol (vapour)
- At high temperatures & frequent puffing PG & VG can form:
  - Acetaldehyde
  - Formaldehyde
  - Acrolein
- Tobacco specific nitrosamines can be present with tobacco extracts & nicotine
- Oxidizing chemicals

Liquid
- Nicotine
- Flavouring
  - Benzaldehyde (cherry flavor)
  - Cinnamaldehyde (cinnamon flavours)
  - Diacetyl (butter flavours)

Battery & coil
- Metals e.g. nickel, chromium, cadmium, lead, tin, silicates

High exposure associated with ‘popcorn lung’, but there are no cases of ‘popcorn lung’ among vapers or smokers (cigarettes also contain diacetyl)

## Examples of toxicant emissions

### Vaping versus cigarette smoke

<table>
<thead>
<tr>
<th>Toxicant</th>
<th>Amount in aerosol</th>
<th>Amount in cigarette</th>
<th>Toxic effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaldehyde</td>
<td>2-14 mcg per 150 puffs</td>
<td>650 mcg per cigarette</td>
<td>Respiratory tract irritant, probable carcinogen</td>
</tr>
<tr>
<td>Acrolein</td>
<td>ND – 42 mcg per 150 puffs</td>
<td>60-140 mcg per cigarette</td>
<td>Respiratory and cardiovascular toxicant, possible carcinogen</td>
</tr>
<tr>
<td>Chromium</td>
<td>0.007 mcg per 10 puffs</td>
<td>0.004 mcg per cigarette</td>
<td>Lung cancer is a major long-term effect</td>
</tr>
<tr>
<td>Formaldehyde</td>
<td>3-56 mcg per 150 puffs</td>
<td>20-100 mcg per cigarette</td>
<td>Respiratory tract irritant, probable carcinogen</td>
</tr>
<tr>
<td>N-Nitrosamines</td>
<td>ND-28 mcg per 150 puffs</td>
<td>0.02-72 mcg per cigarette</td>
<td>Carcinogen</td>
</tr>
<tr>
<td>Toluene</td>
<td>ND-6 mcg per 150 puffs</td>
<td>0.02-73 mcg per cigarette</td>
<td>Headache, depression, cognitive impairment</td>
</tr>
<tr>
<td>Lead</td>
<td>0.03-0.57 mcg per 150 puffs</td>
<td>0.001 mcg per cigarette</td>
<td>Neurotoxin, cardio toxin</td>
</tr>
</tbody>
</table>

ND=not determined

Estimated cancer risk

<table>
<thead>
<tr>
<th>Carcinogens</th>
<th>IARC type</th>
<th>ODMMA unit risk (µg/m³)</th>
<th>Mean concentration (µg/mL)</th>
<th>Mean concentration (µg/mL)</th>
<th>Mean concentration (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaldehyde</td>
<td>2B</td>
<td>2.7 x 10⁻⁶</td>
<td>2.55 x 10⁻⁶</td>
<td>3.3 x 10⁻⁶</td>
<td>4.4 x 10⁻⁶</td>
</tr>
<tr>
<td>Formaldehyde</td>
<td>1</td>
<td>6.0 x 10⁻⁶</td>
<td>1.54 x 10⁻⁵</td>
<td>1.86 x 10⁻⁶</td>
<td>8.07 x 10⁻⁷</td>
</tr>
<tr>
<td>Acrylamide</td>
<td>2B</td>
<td>2.9 x 10⁻⁶</td>
<td>4.55 x 10⁻⁶</td>
<td>2.96 x 10⁻⁶</td>
<td>NR</td>
</tr>
<tr>
<td>Benzo(a)pyrene</td>
<td>1</td>
<td>2.9 x 10⁻³</td>
<td>1.3 x 10⁻⁵</td>
<td>5.9 x 10⁻⁵</td>
<td>NR</td>
</tr>
<tr>
<td>N NN</td>
<td>1</td>
<td>1.8 x 10⁻⁵</td>
<td>3.67 x 10⁻⁶</td>
<td>2.1 x 10⁻⁶</td>
<td>NR</td>
</tr>
<tr>
<td>NNK</td>
<td>1</td>
<td>4.8 x 10⁻⁵</td>
<td>6.83 x 10⁻⁸</td>
<td>2.57 x 10⁻⁵</td>
<td>1.98 x 10⁻⁷</td>
</tr>
<tr>
<td>NNAL</td>
<td>1</td>
<td>4.6 x 10⁻⁵</td>
<td>2.88 x 10⁻⁹</td>
<td>1.64 x 10⁻⁶</td>
<td>8.5 x 10⁻⁷</td>
</tr>
<tr>
<td>Cadmium</td>
<td>1</td>
<td>4.2 x 10⁻⁵</td>
<td>1.99 x 10⁻⁶</td>
<td>9.0 x 10⁻⁶</td>
<td>9.52 x 10⁻⁷</td>
</tr>
<tr>
<td>Lead</td>
<td>2B</td>
<td>1.2 x 10⁻⁵</td>
<td>7.52 x 10⁻⁴</td>
<td>4.8 x 10⁻⁵</td>
<td>7.06 x 10⁻⁵</td>
</tr>
<tr>
<td>Chromium</td>
<td>1</td>
<td>1.5 x 10⁻⁶</td>
<td>BOL</td>
<td>BOL</td>
<td>BOL</td>
</tr>
<tr>
<td>Nickel</td>
<td>2B</td>
<td>2.8 x 10⁻⁶</td>
<td>7.0 x 10⁻⁶</td>
<td>6.9 x 10⁻⁷</td>
<td>3.9 x 10⁻⁷</td>
</tr>
<tr>
<td>Arsenic</td>
<td>1</td>
<td>3.3 x 10⁻⁷</td>
<td>2.2 x 10⁻⁷</td>
<td>2.1 x 10⁻⁷</td>
<td>1.8 x 10⁻⁷</td>
</tr>
</tbody>
</table>

**Mean cancer potency ratio (equation 5)**

<table>
<thead>
<tr>
<th>Mean lifetime cancer risk (equations 6 and 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio to tobacco smoke</td>
</tr>
<tr>
<td>Ratio to nicotine inhaler</td>
</tr>
<tr>
<td>Rods to tobacco smoke</td>
</tr>
<tr>
<td>Rods to nicotine inhaler</td>
</tr>
</tbody>
</table>

**Table 1** Unit risks and average concentrations for IARC type 1 and 2 carcinogens measured in tobacco smoke and other forms of nicotine delivery.

**Graph:**
- **Tobacco smoke**
- **Heat-not-burn products**
- **Vaping**
- **Nicotine inhalator**

**Values:**
- 0.024
- 0.004
- 0.0004

Stephens WE. Tob Control 2017;0:1–8. doi:10.1136/tobaccocontrol-2017-053808
Cell culture and animal studies

ECIG liquid/vapour was associated with:

- Decrease in cell viability (in some but not all studies)
- Changes in oxidative stress
- Increased production of inflammatory mediators
- Reduction in host defence against infection

“Most of these studies revealed adverse effects of ECIGs, although these were less pronounced than with TCIGs.”

TCIG = tobacco cigarettes

“...these in vitro and in vivo exposure studies raise concerns regarding the use of ECIGs, conclusive answers will only be obtained with carefully conducted long-term studies in ECIG users.”

Measurement of tobacco-related toxicants in urine among:
- current exclusive e-cigarette users (n = 247)
- current exclusive cigarette smokers (n = 2411)
- users of both products (dual users) (n = 792)
- never tobacco users (n = 1655)

Compared with exclusive cigarette smokers, exclusive e-cigarette users showed
- 10% to 98% significantly lower concentrations of biomarkers of exposure, including TSNAs, PAHs, most volatile organic compounds, and nicotine
- Comparable concentrations of metals and 3 volatile organic compounds.

\(^{a}\) Statistically significant difference from never users
\(^{b}\) Statistically significant difference cigarette-only users
Does the presence of these substances translate to harm?

- The harm is largely related to exposure
- There is currently no evidence that vaping is associated with disease, **BUT** EC have not been around for long enough to observe this association
- A complicating factor is that most vapers are current or former smokers

“Although e-cigarettes are not without risk, compared to combustible tobacco cigarettes they contain fewer toxicants; can deliver nicotine in a similar manner; show significantly less biological activity in most, but not all, in vitro, animal, and human systems; and might be useful as a cessation aid in smokers who use e-cigarettes exclusively.”

Continuum of harm

EVALI: E-CIGARETTE/VAPING ASSOCIATED LUNG INJURY

- Outbreak of serious acute respiratory damage in US
- As of November 21, the CDC has confirmed 2,290 cases, with 47 deaths.
- Almost all cases vaped THC
- Vitamin E Acetate found in most cases
- Very few cases of EVALI where THC was not used

Source: US CDC
Second-hand vaping

- There is no smoke
- There is no side-stream vapour from the e-cigarette
- Some studies have demonstrated toxicants in second-hand vapour, but at much lower levels than second-hand tobacco smoke
- They do not emit vapour continuously, but only in the ‘cloud’ when exhaled by vapers
- The potential harm of second-hand vapour is not currently known

PAST 30-DAY USE (SMOKING AND VAPING) IN US HIGH-SCHOOLERS 2004-2021

Smoking and Vaping, US High schoolers
National Youth Tobacco Surveys (CDC) 2004-2021
Grades 9-12, ages 15-18 | Past 30-day use

2004-2013 decline in smoking 1% per yr
2013-2021 decline in smoking 1.4% p year

Percent smoking or vaping (past 30 days)

Accelerated decline in smoking from 2013
22.3%
27.5%

Smoking
Vaping

0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
## Threats and Opportunities

<table>
<thead>
<tr>
<th></th>
<th>Individual</th>
<th>Population</th>
</tr>
</thead>
</table>
| **Threats** | • Nicotine dependence  
• Delayed cessation  
• Relapse to tobacco use  
• Dual tobacco & e-cig use  
• Long term toxicant exposure | • Second-hand exposure  
• Re-normalisation of smoking-like behaviour  
• Strengthen Big Tobacco  
• Gateway to smoking for youth  
• Growth of nicotine dependence in population |
| **Opportunities** | • Smoking reduction  
• Cessation  
• Relapse prevention  
• Better health  
• Savings | • Unprecedented reach  
• De-normalisation of smoking  
• Mass substitution  
• Gateway from smoking for youth  
• Increased population quit rates  
• Population health  
• Inequality reduction  
• No cost to health sector |
So, should we be concerned?

- There are likely to be some adverse health effects associated with long-term vaping, so concern is warranted.

- However, this concern needs to be balanced with the concerns for the health and wellbeing of people who continue to smoke.

- For smokers, switching to vaping (and stopping smoking completely) is likely to be associated with a reduction in health risks.
  - This is supported by the current literature
  - To mitigate concern over unknown health risks associated with long-term vaping, ex-smokers can be advised to stop vaping as soon as they feel able not to relapse to smoking

- Appropriate steps can be taken to limit uptake of vaping in young never smokers.
1. Make tobacco products less affordable:
   - Raise tobacco tax by 20%
   - Introduce a minimum retail price for all tobacco products

2. Make tobacco products less available:
   - Support retailers to move away from selling tobacco in the next 3 years, and then cap the number of retailers
   - End tobacco sales in bars and pubs
   - Introduce a cut-off birth date for legal purchase of tobacco, to create future ‘tobacco-free’ generations

3. Make tobacco products less appealing and less addictive:
   - Remove additives and flavours that enhance taste or appeal (e.g. menthol, sugar)
   - Reduce nicotine content to very low levels so they are no longer addictive

4. Do more of what we already do
   Such as: enhanced targeted smoking cessation, mass media campaigns and moving to greater availability of e-cigarettes
Reaching population groups

E-cigarettes need to be affordable, accessible and appealing to smokers, especially those for whom other methods have not worked.
VAPE TO QUIT STRONG
MAXIMISE BENEFITS, MITIGATE RISKS

Maximise benefits

• Smokers must be able to access and afford quality reduced-harm nicotine products
• De-medicalise nicotine
• Responsible promotion to adult smokers, communicating the relative risks and the truth about nicotine.
• Train vape store retailers to offer quit support.
• Educate health care providers and smoking cessation providers about e-cigarettes and supporting vapers to quit smoking.

Minimise risks

• A risk-proportionate regulatory environment that makes more harmful tobacco smoking relatively less affordable, less accessible and palatable (e.g. VLNCs)
• Promote vaping etiquette
• Prohibit marketing and sales to minors
• Monitor products, use and adverse events
“More research is needed”

• **Communications and promotion** - communicate proportionate risk, complete substitution, daily use, use in relapse prevention and what works best to enhance switching.

• **Health effects** - biomarkers, respiratory and cardiovascular endpoints.

• **Impact** - policies, regulations, media coverage, interventions, equity and vulnerable populations.

• **Products and product use** in a range of population groups. New products entering market.
Call To Action

“E-cigarettes threaten public health”

- General respect for both sides.
- Nuanced discussions of findings.
- Open acknowledgement of the legitimate trade-offs that sometimes arise between priority populations.
- Appreciation for interdisciplinary interdependency in our understanding of e-cigarette impacts.
- Regular reflection on one’s own sources of bias

“E-cigarettes benefit public health”
Conclusions

- E-cigarettes are a popular product that help some people cut down and quit smoking.
- They are safer than smoking but not ‘100%’ safe.
- They may be particularly helpful in reducing harms from smoking in groups who have persisting high smoking prevalence.
- We need messaging and policies based on the highest quality available evidence but be willing and ready to change these messages and policies as new evidence emerges.
Thankyou.

Professor Chris Bullen
School of Population Health, the University of Auckland.

c.bullen@auckland.ac.nz
@DrChrisBullen